Fubotv earnings beat by $0.10, revenue topped estimates
Director Kush Parmar reported selling shares of Entrada Therapeutics , Inc. (NASDAQ:TRDA) on July 9, 2025. The sales involved 27,000 shares of common stock, netting approximately $202,554. The transaction comes as the stock trades near its 52-week low of $6.48, having declined over 9% in the past week.
The transactions, executed at a price of $7.502 per share, involved two separate entities. 20,065 shares were sold indirectly through 5AM Ventures V, L.P., while 6,935 shares were sold through 5AM Opportunities I, L.P. Following the transactions, 5AM Ventures V, L.P. holds 3,163,066 shares and 5AM Opportunities I, L.P. holds 1,093,313 shares. InvestingPro analysis suggests the stock is currently undervalued, with 13 additional key insights available to subscribers.
Kush M. Parmar disclaims beneficial ownership of these shares except to the extent of his pecuniary interest. The $238 million market cap company is scheduled to report its next earnings on August 6, 2025.
In other recent news, Entrada Therapeutics has received regulatory approvals from several European Union countries, as well as the United Kingdom (TADAWUL:4280), to commence a new clinical study for Duchenne muscular dystrophy (DMD). The Phase 1/2 clinical study, named ELEVATE-45-201, will explore the safety, tolerability, and effectiveness of the investigational therapy ENTR-601-45. This study will involve approximately 24 ambulatory DMD patients and is scheduled to begin in the third quarter of 2025. H.C. Wainwright analysts have reaffirmed a Buy rating for Entrada Therapeutics, maintaining a price target of $20.00, following these regulatory developments. The study is part of Entrada’s broader strategy to advance its pipeline of exon-skipping drug candidates aimed at treating neuromuscular diseases. Additionally, the company plans to submit global regulatory applications for other exon-skipping candidates, ENTR-601-50 and ENTR-601-51, in the coming years. These developments highlight Entrada’s continued efforts to address unmet medical needs within the DMD community. The company’s approach involves using its proprietary Endosomal Escape Vehicle (EEV™) technology to deliver therapeutics into cells, targeting diseases that have been challenging to treat.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.